ABSTRACT
We consider dosing regimens designed to cure patients by eradicating colony forming units (CFU) such as bacteria. In the field of “population” pharmaco-kinetics/dynamics (PK/PD), inter-individual variability (IIV) of patients is estimated using model parameter statistical distributions. We consider a more probabilistic approach to IIV called stochastic process theory, motivated by the fact that tumor treatment planning uses both approaches. Stochastic process PD can supply additional insights and suggest different dosing regimens due to its emphasis on the probability of complete CFU eradication and its predictions on “pure chance” fluctuations of CFU number per patient when treatment has reduced this integer to less than ~100. To exemplify the contrast between stochastic process PD models and standard deterministic PD models, which track only average CFU number, we analyze, neglecting immune responses, neonatal intravenous gentamicin dosing regimens directed against Escherichia coli. Our stochastic calculations predict that the first dose is crucial for CFU eradication. For example, a single 6 mg/kg dose is predicted to have a higher eradication probability than four daily 4 mg/kg doses. We conclude: (1) neonatal gentamicin dosing regimens with larger first doses but smaller total doses deserve investigation; (2) in general, if standard PK/PD models predict average CFU number drops substantially below 100, the models should be modified to incorporate stochastic effects more accurately, and will then usually make more favorable, or less unfavorable, predictions for front boosting (“hit hard early”). Various caveats against over-interpreting the calculations are given.
Similar content being viewed by others
REFERENCES
Czock D, Markert C, Hartman B, Keller F. Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin Drug Metab Toxicol. 2009;5(5):475–87.
Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev. 2013;65(3):1053–90.
Wu B, Sy SKB, Derendorf H. Principles of applied pharmacokinetic–pharmacodynamic modeling. In: Vinks AA, Derendorf H, Mouton JW, editors. Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. New York: Springer; 2014.
Bulik CC, Nightingale CH, Nicolau DP. Aminoglycosides. In: Vinks AA, Derendorf H, Mouton JW, editors. Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. New York: Springer; 2014.
Vinks AA. Population pharmacokinetic–pharmacodynamic (PK/PD) modeling of anti- infective agents and its applications to individualized therapy. In: Vinks AA, Derendorf H, Mouton JW, editors. Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. New York: Springer; 2014.
Wynn JL, Levy O. Role of innate host defenses in susceptibility to early onset neonatal sepsis. Clin Perinatol. 2010;37(2):307–37.
Weston EJ, Pondo T, Lewis MM, Martell-Cleary P, Morin C, Jewell B, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005–2008. Pediatr Infect Dis J. 2011;30(11):937–41.
Nielsen EI, Sandstrom M, Honore PH, Ewald U, Friberg LE. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet. 2009;48(4):253–63.
Mohamed AF, Nielsen EI, Cars O, Friberg LE. Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother. 2012;56(1):179–88.
Barker CI, Germovsek E, Hoare RL, Lestner JM, Lewis J, Standing JF. Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. Adv Drug Deliv Rev. 2014;73:127–39.
Downie L, Armiento R, Subhi R, Kelly J, Clifford V, Duke T. Community-acquired neonatal and infant sepsis in developing countries: efficacy of WHO’s currently recommended antibiotics–systematic review and meta-analysis. Arch Dis Child. 2013;98(2):146–54.
Hasvold J, Bradford L, Nelson C, Harrison C, Attar M, Stillwell T. Gentamicin resistance among Escherichia coli strains isolated in neonatal sepsis. J Neonatal-Perinatal Med. 2013;6(2):173–7.
Gurney WSC, Nisbet RM. Ecological dynamics. USA: Oxford University Press; 1998.
Grimmett G, Stirzaker D. Probability and random processes. 3rd ed. Oxford: Oxford University Press; 2001.
Tan W. Stochastic models with applications to genetics, cancers, AIDS, and other biomedical systems. London: World Scientific; 2002.
Zaider M, Hanin L. Tumor control probability in radiation treatment. Med Phys. 2011;38(2):574–83.
Marcu LG, Harriss-Phillips WM. In silico modelling of treatment-induced tumour cell kill: developments and advances. Comput Math Methods Med. 2012;2012:960256.
Fakir H, Hlatky L, Li H, Sachs R. Repopulation of interacting tumor cells during fractionated radiotherapy: stochastic modeling of the tumor control probability. Med Phys. 2013;40(12):121716.
Hanin L, Zaider M. Optimal schedules of fractionated radiation therapy by way of the greedy principle: biologically-based adaptive boosting. Phys Med Biol. 2014;59(15):4085–98.
Fowler JF. 21 years of biologically effective dose. Br J Radiol. 2010;83(991):554–68.
Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM. Merging systems biology with pharmacodynamics. Sci Transl Med. 2012;4(126):126ps7.
Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012;25(4):609–34.
Jusko WJ. Moving from basic toward systems pharmacodynamic models. J Pharm Sci. 2013;102(9):2930–40.
Sorger P, Allerheiligen S, Abernethy D, Altman R, Brouwer K, Califano A, et al. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms 2011. Available from: http://www.nigms.nih.gov/News/Reports/Pages/201110-syspharma.aspx.
Croes S, Koop AH, van Gils SA, Neef C. Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2012;45(1–2):90–100.
Tucker SL, Thames HD, Taylor JM. How well is the probability of tumor cure after fractionated irradiation described by Poisson statistics? Radiat Res. 1990;124(3):273–82.
Ovaskainen O, Meerson B. Stochastic models of population extinction. Trends Ecol Evol. 2010;25(11):643–52.
Edelstein-Keshet L. Mathematical models in biology. Philadelphia: SIAM; 2005.
Kendall DG. On the generalized birth and death process. Ann Math Stat. 1948;19:101–17.
Hoff DS, Wilcox RA, Tollefson LM, Lipnik PG, Commers AR, Liu M. Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates. Pharmacotherapy. 2009;29(11):1297–305.
Dersch-Mills D, Akierman A, Alshaikh B, Yusuf K. Validation of a dosage individualization table for extended-interval gentamicin in neonates. Ann Pharmacother. 2012;46(7–8):935–42.
Barclay ML, Begg EJ. Aminoglycoside adaptive resistance: importance for effective dosage regimens. Drugs. 2001;61(6):713–21.
McLanahan ED, El-Masri HA, Sweeney LM, Kopylev LY, Clewell HJ, Wambaugh JF, et al. Physiologically based pharmacokinetic model use in risk assessment—why being published is not enough. Toxicol Sci Off J Soc Toxicol. 2012;126(1):5–15.
Cooper AC, Commers AR, Finkelstein M, Lipnik PG, Tollefson LM, Wilcox RA, et al. Otoacoustic emission screen results in critically ill neonates who received gentamicin in the first week of life. Pharmacotherapy. 2011;31(7):649–57.
Reynolds LF, Mailman TL, McMillan DD. Gentamicin in neonates at risk for sepsis—peak serum concentrations are not necessary. Paediatr Child Health. 2012;17(6):310–2.
Fjalstad JW, Laukli E, van den Anker JN, Klingenberg C. High-dose gentamicin in newborn infants: is it safe? Eur J Pediatr. 2013.
Acknowledgments
Support from NIH NCI ICBP U54CA149233 (LH and RKS), from the University of California Undergraduate Research Program (NS), and from the Cleveland Clinic Foundation (TR) is gratefully acknowledged. We thank Prof. L. Hanin for useful criticisms.
Conflict of interest
There are no conflicts of interest related to the work in the manuscript.
Confidentiality
Use of the information in this manuscript for commercial, noncommercial, research, or purposes other than peer review not permitted prior to publication without the expressed written permission from the author.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 241 kb)
Rights and permissions
About this article
Cite this article
Radivoyevitch, T., Siranart, N., Hlatky, L. et al. Stochastic Process Pharmacodynamics: Dose Timing in Neonatal Gentamicin Therapy as an Example. AAPS J 17, 447–456 (2015). https://doi.org/10.1208/s12248-014-9715-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-014-9715-3